Karthick Subramanian

Dr. Karthick Subramanian

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Pharmacology and Pharmacotherapeutics
Verified
Journal Article
Open access
PDF file
CHARANRAJ GOUD ALLADICHARANRAJ GOUD ALLADI
CHARANRAJ GOUD ALLADI
AMAnbarasan Mohan
Anbarasan Mohan
HSHemant Deepak Shewade
Hemant Deepak Shewade
RRRavi Philip Rajkumar
Ravi Philip Rajkumar
SASurendiran Adithan
Surendiran Adithan
KSKarthick Subramanian
Karthick Subramanian
Objective: To determine the adverse drug reaction (ADR) profile of risperidone and their association with dopamine (DRD2 − 141 C Ins/Del/rs1799732) and serotonin receptor (5HTR2C −759 C>T/rs3813929) gene polymorphisms in patients with schizophrenia. Materials and Methods: The study was conducted among 289 patients who were diagnosed with schizophrenia and were on treatment with risperidone (4–8 mg/day)-based therapy for a minimum of 4 weeks. Genotyping was carried by real-time quantitative polymerase chain reaction. All the patients were observed for the occurrences of ADRs during the study. Changes in prolactin levels and body weight were analyzed for a subgroup of 102 and 97 patients, respectively. Results: Risperidone-induced extrapyramidal symptoms (EPSs) were seen in 36.7% of patients. Among them, tremors were the most common symptom 31.8%. Risperidone-induced hyperprolactinemia and weight gain were seen in 87.2% and 53.6% in subgroup patients. Adverse effects such as sedation, gastrointestinal effects, and amenorrhea were seen in 9.7% (28/289), 5.1% (15/289), and 6.1% (7/114), respectively. Occurrence of DRD2 − 141 Ins/Del and Del/Del polymorphisms were significantly associated with increased prolactin levels in response to risperidone (odds ratio [OR] = 10.45; 95% confidence interval = 1.29–84.89,P = 0.004). No such association was observed with 5HTR2C (−759 C>T) polymorphism. Weight gain and EPS were not associated with the above genetic polymorphisms. Conclusion: Hyperprolactinemia, weight gain, and EPSs (>36.7%) were common adverse effects of risperidone. DRD2 – 141C Ins/Del and Del/Del polymorphisms were significantly associated with increased prolactin levels (OR = 10.45) in response to risperidone.

1 October 2017 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
KSKarthick Subramanian
Karthick Subramanian
SSSiddharth Sarkar
Siddharth Sarkar
SKShivanand Kattimani
Shivanand Kattimani

30 November 2016 in Journal of Child and Adolescent Psychiatric Nursing
Verified
Journal Article
Closed access
PDF file
HMHarshini Manohar
Harshini Manohar
KSKarthick Subramanian
Karthick Subramanian
PKPreeti Kandasamy
Preeti Kandasamy
VPVenkatalakshmi Penchilaiya
Venkatalakshmi Penchilaiya
AAAnandbabu Arun
Anandbabu Arun

1 December 2017 in Psychiatry Research
Verified
Journal Article
Closed access
KSKarthick Subramanian
Karthick Subramanian
SSSiddharth Sarkar
Siddharth Sarkar
SKShivanand Kattimani
Shivanand Kattimani
RRRavi Philip Rajkumar
Ravi Philip Rajkumar
VPVenkatalakshmi Penchilaiya
Venkatalakshmi Penchilaiya

17 November 2016 in International Journal of Psychiatry in Clinical Practice
Verified
Journal Article
Closed access
SKShivanand Kattimani
Shivanand Kattimani
KSKarthick Subramanian
Karthick Subramanian
SSSiddharth Sarkar
Siddharth Sarkar
RRRavi Philip Rajkumar
Ravi Philip Rajkumar
SBShanmuganathan Balasubramanian
Shanmuganathan Balasubramanian
Objectives: To identify the prevalence and correlates of bipolar I patients with a lifetime history of suicide attempt. Materials and methods: Bipolar I disorder was diagnosed in 150 patients as per DSM-IV-TR criteria. Their lifetime suicide risk was assessed using the Columbia Suicide Severity Rating Scale. NIMH retrospective Life Chart Methodology was used to chart the illness course. Medication Adherence Rating Scale (MARS) and Pittsburgh Sleep Quality Index (PSQI) were used to assess the recent adherence and subjective sleep quality, respectively. The suicide attempters were compared with non-attempters on individual variables. Results: Around 23% had a positive lifetime history of suicide attempt. They were predominantly female, had an index (first ever) episode of depression, spent more proportion of time being ill, especially in depressive or mixed episode phase. Comorbid substance use disorder along with suicidal attempts was seen only in males. Suicide attempters displayed poor medication adherence attitudes for medications taken during the past week and reported impaired sleep quality for the previous month. Conclusions: A positive history of lifetime suicide attempt was significantly associated with a worse course of bipolar I disorder. Effective treatment of depressive episodes, addressing non-adherence, substance use and sleep problems can reduce the suicide risk in such patients. Retrospective design of the study and recall bias are some of the limitations.

1 April 2020 in Journal of Neurosciences in Rural Practice
Verified
Journal Article
Open access
PDF file
KSKarthick Subramanian
Karthick Subramanian
VMVikas Menon
Vikas Menon
SSSiddharth Sarkar
Siddharth Sarkar
VCVigneshvar Chandrasekaran
Vigneshvar Chandrasekaran
NSNivedhitha Selvakumar
Nivedhitha Selvakumar
Background Suicide is the leading contributor to mortality in bipolar disorder (BD). A history of suicidal attempt is a robust predictive marker for future suicide attempts. Personality profiles and coping strategies are the areas of contemporary research in bipolar suicides apart from clinical and demographic risk factors. However, similar research in developing countries is rarer. Objectives The present study aimed to identify the risk factors associated with suicidal attempts in BD type I (BD-I). Materials and Methods Patients with BD-I currently in clinical remission (N = 102) were recruited. Sociodemographic details and the clinical data were collected using a semistructured pro forma. The psychiatric diagnoses were confirmed using the Mini-International Neuropsychiatric Interview 5.0. The National Institute of Mental Health–Life Chart Methodology Clinician Retrospective Chart was used to chart the illness course. Presumptive Stressful Life Events Scale, Coping Strategies Inventory Short Form, Buss–Perry aggression questionnaire, Past Feelings and Acts of Violence, and Barratt Impulsivity scale were used to assess the patient’s stress scores, coping skills, aggression, violence, and impulsivity, respectively. Statistical Analysis Descriptive statistics were used for demographic details and characteristics of the illness course. Binary logistic regression analyses were performed to identify the predictors for lifetime suicide attempt in BD-I. Results A total of 102 patients (males = 49 and females = 53) with BD-I were included. Thirty-seven subjects (36.3%) had a history of suicide attempt. The illness course in suicide attempters more frequently had an index episode of depression, was encumbered with frequent mood episodes, especially in depression, and had a higher propensity for psychiatric comorbidities. On binary logistic regression analysis, the odds ratios (ORs) for predicting a suicide attempt were highest for positive family history of suicide (OR: 13.65, 95% confidence interval [CI]: 1.28–145.38, p = 0.030), followed by the presence of an index depressive episode (OR: 6.88, 95% CI: 1.70–27.91, p = 0.007), and lower scores on problem-focused disengagement (OR: 0.72, 95% CI: 0.56–0.92, p = 0.009). Conclusion BD-I patients with lifetime suicide attempt differ from non-attempters on various course-related and temperamental factors. However, an index episode depression, family history of suicide, and lower problem-focused engagement can predict lifetime suicide attempt in patients with BD-I.